194 related articles for article (PubMed ID: 22208596)
1. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia.
Sethi KD; Rodriguez R; Olayinka B
J Med Econ; 2012; 15(3):419-23. PubMed ID: 22208596
[TBL] [Abstract][Full Text] [Related]
2. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).
Bensmail D; Hanschmann A; Wissel J
J Med Econ; 2014 Sep; 17(9):618-25. PubMed ID: 24841450
[TBL] [Abstract][Full Text] [Related]
3. The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.
Dressler D; Kupsch A; Seitzinger A; Paus S
Eur J Neurol; 2014 Mar; 21(3):459-62. PubMed ID: 24433495
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
Truong D; Duane DD; Jankovic J; Singer C; Seeberger LC; Comella CL; Lew MF; Rodnitzky RL; Danisi FO; Sutton JP; Charles PD; Hauser RA; Sheean GL
Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
[TBL] [Abstract][Full Text] [Related]
5. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
6. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.
Quagliato EM; Carelli EF; Viana MA
Clin Neuropharmacol; 2010; 33(1):22-6. PubMed ID: 19959960
[TBL] [Abstract][Full Text] [Related]
7. How satisfied are cervical dystonia patients after 3Â years of botulinum toxin type A treatment? Results from a prospective, long-term observational study.
Colosimo C; Charles D; Misra VP; Maisonobe P; Om S;
J Neurol; 2019 Dec; 266(12):3038-3046. PubMed ID: 31501975
[TBL] [Abstract][Full Text] [Related]
8. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
[TBL] [Abstract][Full Text] [Related]
9. A 17-year experience of abobotulinumtoxina in cervical dystonia.
Vivancos-Matellano F; Ybot-Gorrin I; Diez-Tejedor E
Int J Neurosci; 2012 Jul; 122(7):354-7. PubMed ID: 22329596
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections.
Slawek J; Friedman A; Potulska A; Krystkowiak P; Gervais C; Banach M; Ochudlo S; Budrewicz S; Reclawowicz D; Rynkowski M; Opala G
Funct Neurol; 2007; 22(2):95-100. PubMed ID: 17637212
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
Factor SA; Molho ES; Evans S; Feustel PJ
Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y
Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474
[TBL] [Abstract][Full Text] [Related]
13. Cervical dystonia: improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography.
Nijmeijer SW; Koelman JH; Standaar TS; Postma M; Tijssen MA
Parkinsonism Relat Disord; 2013 May; 19(5):533-8. PubMed ID: 23466060
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of intradermal injection of botulinum toxin for the treatment of oily skin.
Rose AE; Goldberg DJ
Dermatol Surg; 2013 Mar; 39(3 Pt 1):443-8. PubMed ID: 23293895
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
[TBL] [Abstract][Full Text] [Related]
17. The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment.
Skogseid IM; Kerty E
Eur J Neurol; 2005 Mar; 12(3):163-70. PubMed ID: 15693803
[TBL] [Abstract][Full Text] [Related]
18. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia.
Cano SJ; Hobart JC; Edwards M; Fitzpatrick R; Bhatia K; Thompson AJ; Warner TT
Neurology; 2006 Dec; 67(12):2230-2. PubMed ID: 17190951
[TBL] [Abstract][Full Text] [Related]
19. Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA.
Coleman C; Hubble J; Schwab J; Beffy JL; Picaut P; Morte C
Int J Neurosci; 2012 Jul; 122(7):358-62. PubMed ID: 22356470
[TBL] [Abstract][Full Text] [Related]
20. Botulinum A toxin treatment in spasmodic torticollis: report of 56 patients.
Poungvarin N; Viriyavejakul A
J Med Assoc Thai; 1994 Sep; 77(9):464-70. PubMed ID: 7706965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
